| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/30/2003 | CN1413583A Low dose diclofenac sodium lozenge and its preparation method |
| 04/30/2003 | CN1413582A Dimethyldiguanide hydrochloride enteric solubility tablet and its preparation method |
| 04/30/2003 | CN1413581A Pharmaceutical preparation containing northeast cryrtominetin medicinal preparation and its new use |
| 04/30/2003 | CN1413580A Elemene antitumor medicine and its preparation method |
| 04/30/2003 | CN1413576A Solid-state liposome containing calcareous and its preparation method |
| 04/30/2003 | CN1107072C Programing cell death induced molecule II |
| 04/30/2003 | CN1107069C Derivatives of camptothecin for use in treating cancer and its use |
| 04/30/2003 | CN1107068C 2-amino-7-(1-substituted-2-hyroxyethyl)-3.5-diphydro-pyrrolo (3,2-D) pyrimidine-4-ones |
| 04/30/2003 | CN1107067C Carbapenem compounds, use and intermediate compounds thereof |
| 04/30/2003 | CN1107066C Diaza-spiro [3,5] nonane derivatives |
| 04/30/2003 | CN1107061C Chemotaxis cell factor receptor-3 receptor antagonists |
| 04/30/2003 | CN1107060C Piperazingl cyclohexanols and compositions containing same and use thereof |
| 04/30/2003 | CN1107059C Azole derivative |
| 04/30/2003 | CN1107058C Subsitituted isoxazoles for treatment of inflammation |
| 04/30/2003 | CN1106854C Ointment for treating burn and scald and its preparation process |
| 04/30/2003 | CN1106852C Medicine for treating cough and its preparation process |
| 04/30/2003 | CN1106847C Medicated wine for curing rheumatism and rheumatoid disease and its preparing method |
| 04/30/2003 | CN1106845C Process for preparing solid-state-microspherical vascular cuppository of sodium alginate |
| 04/30/2003 | CN1106844C Treatment of optic nerve disorder with prostanoic acid compounds |
| 04/30/2003 | CN1106843C Specific anti-dizziness drug and prescription thereof |
| 04/30/2003 | CN1106842C Usage of glutathione accelerator in preparating medicine for treating macular degeneration |
| 04/30/2003 | CN1106841C Compositions for treatment of skin disorders |
| 04/30/2003 | CN1106840C Naringin and naringenin as 3-hydroxyl-3-methylglutaryl CoA (HMG-CoA) reductase inhibitor |
| 04/30/2003 | CN1106839C Controlled release of steroids from sugar |
| 04/30/2003 | CN1106836C Sustained release and implantation type fluorouracil medicine and method for preparing same |
| 04/30/2003 | CN1106830C 稳定的油包水乳状液体系 Stable oil-in-water emulsion system |
| 04/30/2003 | CN1106794C Compound preparation for treating coccidiosis |
| 04/29/2003 | USRE38103 Preferential, nontoxic oxidoreductase inhibitors such as 5-Methanesulfonamido-6-(2,4-difluorophenylthio)-1-indanone administered for prophylaxis of gastrointestinal disorders |
| 04/29/2003 | USRE38102 Use of a pyridazinone derivative |
| 04/29/2003 | US6555710 Aminobenzophenones as inhibitors of IL-1 β and TNF-α |
| 04/29/2003 | US6555702 Beta-cyanostyrene derivatives to treat inflammation, immunological diseases, or diabetes. |
| 04/29/2003 | US6555700 1,3-propane diol esters and ethers and methods for their use in drug delivery |
| 04/29/2003 | US6555693 Compounds that affect the expression of genes essential for the proliferation of the pathogen; promoters or gene expression inhibition; binding to double-stranded DNA; fungicides; bactericides; viricides |
| 04/29/2003 | US6555689 Intermediates useful for the preparation of antihistaminic piperidine derivatives |
| 04/29/2003 | US6555684 Pyrimidinyl compounds for treatment of central nervous system disorders |
| 04/29/2003 | US6555677 Phase transfer catalyzed glycosidation of an indolocarbazole |
| 04/29/2003 | US6555676 Antitumor agents |
| 04/29/2003 | US6555675 Dinucleoside polyphosphates which facilitate secretory mechanisms, i.e. increasing the hydration of mucus secretions, stimulating the production of mucins and increasing ciliary beat frequency to facilitate clearance |
| 04/29/2003 | US6555667 Hypoxia-regulated genes |
| 04/29/2003 | US6555665 Glycosidation of 4,5-epoxymorphinan-6-ols |
| 04/29/2003 | US6555586 Treating obesity, anxiety disorder, post-traumatic stress disorder, premenstrual syndrome, attention deficit disorder, Tourette syndrome, bulimia nervosa or Shy Drager Syndrome by administering a hydroxycycloalkanephenethyl amine |
| 04/29/2003 | US6555585 For decreasing amphetamine-induced hyperactivity |
| 04/29/2003 | US6555583 Therapies for treating pulmonary diseases |
| 04/29/2003 | US6555582 Eye treatments using synthetic thyroid hormone compositions |
| 04/29/2003 | US6555581 Levothyroxine compositions and methods |
| 04/29/2003 | US6555579 Methods for reducing atherosclerotic plaques |
| 04/29/2003 | US6555578 Thyromimetic antiobesity agents |
| 04/29/2003 | US6555577 Compounds, their preparation and use |
| 04/29/2003 | US6555576 Method for treating exercise induced asthma |
| 04/29/2003 | US6555575 Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease |
| 04/29/2003 | US6555573 Comprising a cold compounded mixture of a compound that promotes synthesis of nerve growth factor, an aldose reductase inhibitor, antioxidant and carrier; side effect reduction; partial recovery of neurological function in some cases |
| 04/29/2003 | US6555571 3-methyl -chromane or thiochromane derivatives |
| 04/29/2003 | US6555570 Growth hormone secretagogous with improved bioavailability |
| 04/29/2003 | US6555569 Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection |
| 04/29/2003 | US6555568 3-(4,5,7-trifluorobenzothiazol-2-yl)methyl-indole-N-acetic acid, ethyl ester for example; treating angiogenesis, hyperglycemia, hyperlipidemia and chronic complications arising from diabetes mellitus |
| 04/29/2003 | US6555566 Methods and materials for treating and preventing inflammation of mucosal tissue |
| 04/29/2003 | US6555565 Apoptosis inhibitor |
| 04/29/2003 | US6555564 Such as sleep apnea (central and obstructive); administering a glutamate receptor antagonist that exerts its effects only in the central nervous system, for example, memantine, or amantadine |
| 04/29/2003 | US6555562 2-Carboxybenzoyl-(N'-3,5-dichloroisonicotinoyl)-L-4aminophenyl alanine, for example; inhibit the binding of alpha-4 integrins to their ligands, use to treat immune or inflammatory disorders |
| 04/29/2003 | US6555561 Diaminopyridine-containing thiourea inhibitors of herpes viruses |
| 04/29/2003 | US6555558 Oral dosage self-emulsifying formulations of pyranone protease inhibitors |
| 04/29/2003 | US6555557 2,3-disubstituted pyridine derivatives, process for the preparation thereof, drug compositions containing the same and intermediates for the preparation |
| 04/29/2003 | US6555556 N-(4-(1-acetimidoylpiperidin-4-yl)oxyphenyl)-N-((E)-3-(3 -amidinophenyl)-2-methyl-2-propenyl)sulfamoylacetic acid dihydrochloride for example; factor Xa inhibitors |
| 04/29/2003 | US6555554 Isoindolines, method of use, and pharmaceutical compositions |
| 04/29/2003 | US6555551 E.g. enalapril maleate, by mixing an Angiotensin Converting Enzyme (ACE) inhibitor with an alcohol, adding an aqueous solution of a metal compound, mixing to clarity, blending an excipient to form granulate, drying, adding lubricant |
| 04/29/2003 | US6555550 Musarinic agonists and antagonists |
| 04/29/2003 | US6555548 Administering therapeutically effective amount of active agent selected from the group consisting of a heterocyclic amine-type compound, a substituted phenylazacycloalkane-type compound, and a cabergoline-type compound, and their salts |
| 04/29/2003 | US6555547 And a cyclic guanosine monophosphate(cGMP)-specific phosphodiesterase inhibitor such as exisulind |
| 04/29/2003 | US6555546 Use of 5HT3 antagonists for promoting intestinal lavage |
| 04/29/2003 | US6555545 Adenosine, caffeine, and 8-styryl-1,3,7-alkyl xanthine derivatives as wound healing agents |
| 04/29/2003 | US6555544 9-hydroxyrisperidone palmitate ester having a surfactant adsorbed to the surface thereof; for administration via intramuscular or subcutaneous injection; treating psychological and neurodegenerative disorders |
| 04/29/2003 | US6555543 Inhibiting the effects of platelet activating factor (PAF). |
| 04/29/2003 | US6555542 Sulfonamide lactam inhibitors of FXa and method |
| 04/29/2003 | US6555541 Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions |
| 04/29/2003 | US6555540 Combinations of aldose reductase inhibitors and selective cyclooxygenase-2 inhibitors |
| 04/29/2003 | US6555539 For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis |
| 04/29/2003 | US6555537 Piperazine derivatives and their use as anti-inflammatory agents |
| 04/29/2003 | US6555535 Tricyclic biphenyl sulfonamide matrix metalloproteinase inhibitors |
| 04/29/2003 | US6555534 Method and compositions for the control or eradication of Helicobacter pylori |
| 04/29/2003 | US6555532 Using estrogen receptor antagonists such as tamoxifen |
| 04/29/2003 | US6555531 Weight promoting composition, method, and product |
| 04/29/2003 | US6555530 Administering a mixture of selective estrogen receptor modulators (SERMs), or estrogens with delta-gonadien-21-ol-3,20-diones of given formula |
| 04/29/2003 | US6555529 Remedies for intramedullary diseases |
| 04/29/2003 | US6555528 Protease inhibitor |
| 04/29/2003 | US6555527 Hematopoietic, myeloprotecting, antitumor immune cells generating and radiosensitizing polysaccharide isolated from Panax ginseng |
| 04/29/2003 | US6555526 Trehalos; Sjogren syndrome. |
| 04/29/2003 | US6555524 Ketolide antibiotics |
| 04/29/2003 | US6555523 Use of cirsiliol and derivatives to treat infections |
| 04/29/2003 | US6555519 O-glucosylated benzamide SGLT2 inhibitors and method |
| 04/29/2003 | US6555518 2',2'-difluoronucleosides for suppressing rejection of transplants in mammals; for treatment of autoimmune diseases |
| 04/29/2003 | US6555377 Process for production of mammalian cell lines |
| 04/29/2003 | US6555368 Single-chain antibody introduced into the minor capsid proteins so that the adenoviral vector can be targeted to a particular cell type |
| 04/29/2003 | US6555356 Methods for microbial regulation |
| 04/29/2003 | US6555146 Sugar-free foodstuff products |
| 04/29/2003 | US6555141 L-ergothioneine, Milk thistle, and S-adenosylmethionine for the prevention, treatment and repair of liver damage |
| 04/29/2003 | US6555140 Comprising spermine, spermidine, and selenium wherein the spermidine or spermine are synthetically derived. |
| 04/29/2003 | US6555139 Preparation of micron-size pharmaceutical particles by microfluidization |
| 04/29/2003 | US6555138 Polyethylene glycol matrix pellets for greasy, oily or sticky drug substances |
| 04/29/2003 | US6555136 Pharmaceutical dosage form for pulsatile delivery of methylphenidate |
| 04/29/2003 | US6555135 Comicronized with excipient having no therapeutic activity that is not a surfactant. |